

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.

MONROE, LOUISIANA

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

JUNE 30, 2024

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
JUNE 30, 2024

CONTENTS

	<u>PAGE</u>
Independent Auditors' Report.....	1-4
Statement of Financial Position.....	5
Statement of Activities.....	6
Statement of Functional Expenses.....	7
Statement of Cash Flows.....	8
Notes to Financial Statements.....	9-17
SUPPLEMENTAL INFORMATION	
Schedule I - Schedule of Financial Position.....	18-19
Schedule II - Schedule of Activities.....	20-21
Schedule III - Schedule of Cash Flows.....	22-23
Schedule IV - Schedule of Functional Expenses.....	24-26
Schedule V - Schedule of Compensation, Benefits, and Other Payments to Agency Head or Chief Executive Officer.....	27
COMPLIANCE REPORTS	
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	28-29
SCHEDULE OF FINDINGS AND QUESTIONED COSTS.....	30
SCHEDULE OF PRIOR YEAR FINDINGS.....	31

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.

VIOLET M. ROUSSEL, CPA, APC
JAY CUTHBERT, CPA, APAC
DAWN WHITSTINE, CPA, APC



America Counts on CPAs®

Certified Public Accountants
3007 Armand Street
Monroe, Louisiana 71201
Telephone (318) 322-5156
Facsimile (318) 323-6331

- *Accounting & Auditing*
 - HUD Audits
 - Non-Profit Organizations
 - Governmental Organizations
- *Business & Financial Planning*
- *Tax Preparation & Planning*
 - Individual & Partnership
 - Corporate & Fiduciary
- *Bookkeeping & Payroll Services*

PAM BATTAGLIA, CPA
JOHN R. FORSELL, IV, CPA
NICK RICHARDSON, CPA

ROWLAND H. PERRY, CPA-Retired
CHARLES JOHNSON, JR., CPA-Retired

INDEPENDENT AUDITORS' REPORT

Board of Directors
Northeast Louisiana Sickle Cell Anemia Foundation, Inc.
Monroe, Louisiana

Report on the Financial Statements

We have audited the accompanying financial statements of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of June 30, 2024, and the related statements of activities, functional expenses, and cash flows for the year ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Northeast Louisiana Sickle Cell Anemia Foundation, Inc. as of June 30, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion

on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The schedules I, II, III, IV and V on pages 18 through 27 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 16, 2024 on our consideration of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to

provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting and compliance.

Johnson Perry Roussel & Cuthbert, LLP

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.
CERTIFIED PUBLIC ACCOUNTANTS
Monroe, Louisiana
December 16, 2024

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF FINANCIAL POSITION
AS OF JUNE 30, 2024

ASSETS

CURRENT ASSETS

Cash and Cash Equivalents	\$ 75,844
Certificate of Deposit	17,121
Grant Receivable	1,390
Unconditional Promises to Give - United Way Service Funding for Next Fiscal Year	15,000
<u>TOTAL CURRENT ASSETS</u>	<u>109,355</u>

FIXED ASSETS

Land, Buildings, and Equipment, Net	<u>95,921</u>
-------------------------------------	---------------

<u>NET FIXED ASSETS</u>	<u>95,921</u>
-------------------------	---------------

<u>TOTAL ASSETS</u>	<u>205,276</u>
---------------------	----------------

LIABILITIES & NET ASSETS

CURRENT LIABILITIES

Deferred Revenue	<u>249,024</u>
------------------	----------------

<u>TOTAL CURRENT LIABILITIES</u>	<u>249,024</u>
----------------------------------	----------------

<u>TOTAL LIABILITIES</u>	<u>249,024</u>
--------------------------	----------------

NET ASSETS

Without Donor Restrictions	(67,673)
With Donor Restrictions	<u>23,925</u>

<u>TOTAL NET ASSETS</u>	<u>(43,748)</u>
-------------------------	-----------------

TOTAL LIABILITIES AND <u>NET ASSETS</u>	<u>\$ 205,276</u>
--	-------------------

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2024

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
<u>SUPPORT AND REVENUE</u>			
<u>SUPPORT</u>			
Contributions	\$ 15,369	\$ -	\$ 15,369
Grants	41,200	147,071	188,271
Other Income	-	-	-
Net Assets Released from Restrictions	<u>141,852</u>	<u>(141,852)</u>	<u>-</u>
<u>TOTAL SUPPORT</u>	<u>198,421</u>	<u>5,219</u>	<u>203,640</u>
<u>REVENUE</u>			
Special Events	(2,481)	-	(2,481)
Interest Revenue	<u>17</u>	<u>-</u>	<u>17</u>
<u>TOTAL REVENUE</u>	<u>(2,464)</u>	<u>-</u>	<u>(2,464)</u>
<u>TOTAL SUPPORT AND REVENUE</u>	<u>195,957</u>	<u>5,219</u>	<u>201,176</u>
<u>EXPENSES</u>			
<u>PROGRAM SERVICES</u>	<u>140,389</u>	<u>-</u>	<u>140,389</u>
<u>SUPPORTING SERVICES</u>			
Management & General	<u>123,991</u>	<u>-</u>	<u>123,991</u>
<u>TOTAL SUPPORTING SERVICES</u>	<u>123,991</u>	<u>-</u>	<u>123,991</u>
<u>TOTAL FUNCTIONAL EXPENSES</u>	<u>264,380</u>	<u>-</u>	<u>264,380</u>
Change in Net Assets	(68,423)	5,219	(63,204)
<u>NET ASSETS AT BEGINNING OF YEAR</u>	<u>750</u>	<u>18,706</u>	<u>19,456</u>
<u>NET ASSETS AT END OF YEAR</u>	<u>\$ (67,673)</u>	<u>\$ 23,925</u>	<u>\$ (43,748)</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2024

	General and Administrative	Program	Total
Personnel Costs			
Salaries and Wages	\$ 43,011	\$ 50,491	\$ 93,502
Payroll Taxes and Other Fringe Benefits	3,522	4,132	7,654
Total Personnel Costs	46,533	54,623	101,156
Other Expenses			
Advertising	5,209	6,115	11,324
Automobile Expense	147	172	319
Bank Service Charges	-	-	-
Depreciation Expense	4,798	5,633	10,431
Insurance	2,800	3,288	6,088
Interest	-	-	-
Maintenance	946	1,110	2,056
Office Expense	19,045	22,358	41,403
Other Program Expense	873	1,024	1,897
Postage and Delivery	134	158	292
Printing and Publication	1,551	1,820	3,371
Professional Fees	20,432	-	20,432
Repairs and Maintenance	13,735	16,124	29,859
Specific Assistance to Individuals	-	18,822	18,822
Storage	281	329	610
Telephone	-	-	-
Travel	920	1,080	2,000
Utilities	6,587	7,733	14,320
<u>TOTAL EXPENSES</u>	<u>\$ 123,991</u>	<u>\$ 140,389</u>	<u>\$ 264,380</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED JUNE 30, 2024

CASH FLOWS FROM OPERATING ACTIVITIES:

Change in Net Assets	\$ (63,204)
Adjustments to Reconcile Change in Unrestricted Net Assets to Net Cash Provided by Operating Activities	
Depreciation and Amortization	10,431
Interest Earned on Certificate of Deposit	(17)
(Increase) Decrease in:	
Grants Receivable	4,616
Unconditional Promises to Give	(1,500)
Increase (Decrease) in:	
Deferred Revenue	100,170
Accrued Liabilities	-

NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES

50,496

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of Fixed Assets	-
Gain on Investments	-

NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES

-

CASH FLOWS FROM FINANCING ACTIVITIES:

Payments on Line of Credit	-
----------------------------	---

NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES

-

NET INCREASE (DECREASE) IN CASH

50,496

CASH AT BEGINNING OF PERIOD

25,348

CASH AT END OF PERIOD

\$ 75,844

Interest Paid	-
Income Taxes Paid	-

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES:

Nature of Activities

The Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (the Foundation) is a private nonprofit organization domiciled in the State of Louisiana at Monroe, Louisiana. The Foundation is recognized as a tax-exempt (non-profit) organization under section 501(c)(3) of the Internal Revenue Service Code. The Foundation is supported primarily through state and private grants, contributions and donations from members, and fundraisers. The objective of the Foundation is primarily to provide services to persons born with sickle cell anemia, a hereditary disorder. Such services include educational programs, patient assistance programs, genetic counseling, research, and social services. A Board of Directors consisting of fifteen (15) members governs the Foundation. The Board Members receive no compensation.

Method of Accounting

The financial statements have been prepared on the accrual method of accounting and in conformity with the standards promulgated by the American Institute of Certified Public Accountants in its *Audit and Accounting Guide for Not-for-Profit Organizations*.

Basis of Presentation

The financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("US GAAP"), which require the Foundation to report information regarding its financial position and activities according to the following net asset classifications:

Net Assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation and the board of directors.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Basis of Presentation (Continued)

Net Assets with donor restrictions: Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statement of activities.

Promises to Give and Contributions

Contributions are recognized when the donor makes a promise to give to the Foundation that is, in substance, unconditional. Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Revenue Recognition

Revenue from Exchange Transactions: The Foundation recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers*, as amended. ASU 2014-09 applies to exchange transactions with customers that are bound by contracts or similar arrangements and establishes a performance obligation approach to revenue recognition. The Foundation records the following exchange transaction revenue in its statements of activities and changes in net assets for the year ending June 30, 2024:

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Revenue Recognition (Continued)

Special Fundraising Event Revenue

The Foundation conducts special events in which a portion of the gross proceeds paid by the participant represents payment for the direct cost of the benefits received by the participant at the event--the exchange component, and a portion represents a contribution to the Foundation. Unless a verifiable objective means exists to demonstrate otherwise, the fair value of meals and entertainment provided at special events is measured at the actual cost to the Foundation. The contribution component is the excess of the gross proceeds over the fair value of the direct donor benefit. The direct costs of the special events, which ultimately benefit the donor rather than the Foundation, are recorded as costs of direct donor benefits in the (consolidated) statement of activities and changes in net assets. The performance obligation is delivery of the event, which is usually accompanied by a presentation. The event fee is set by the Foundation. FASB ASU 2014-09 requires allocation of the transaction price to the performance obligation(s). Accordingly, the Foundation separately presents in its statement of activities and changes in net assets or notes to financial statements the exchange and contribution components of the gross proceeds from special events. Special event fees collected by the Foundation in advance of its delivery are initially recognized as liabilities (deferred revenue) and recognized as special event revenue after delivery of the event. For special event fees received before year-end for an event to occur after year-end, the Foundation follows AICPA guidance where the inherent contribution is conditioned on the event taking place and is therefore treated as a refundable advance along with the exchange component.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES: (Continued)

Public Support and Revenue

Grants and other contributions of cash and other assets are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Contributions received with donor-imposed restrictions that are met in the same year in which the contributions are received are classified as contributions without donor restrictions.

Contributions of donated noncash assets are recorded at their fair values in the period received. Contributions of donated services that created or enhance nonfinancial assets or that require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation, are recorded at their fair values in the period received.

The accounting and reporting of grants is determined by the underlying substance of the transaction. A grant may be accounted for as contribution, an exchange transaction, or a combination of the two. If it is determined to be a contribution, a grant may be considered a conditional or an unconditional grant.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

JUNE 30, 2024

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Income Taxes

The Foundation is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. The Foundation believes that it has appropriate support for any tax provisions taken, and as such, does not have any uncertain tax positions that are material to the financial statements. The Foundations' Federal Return of Organization Exempt from Income Tax (form 990) for the years ended June 30, 2021, 2022, 2023, and 2024 are subject to examination by the IRS.

Advertising

The Foundation expenses advertising costs as they are incurred. For the year ended June 30, 2024, advertising expense was immaterial.

Reserve for Bad Debts

Accounts receivable are reviewed by management for bad debts monthly and it has been determined that there is no requirement for an allowance for doubtful accounts as of June 30, 2024.

Donated Services - Volunteers

No amounts have been reported in the financial statements for donated goods and services because no objective basis is available to measure the value of such services. Board members receive no compensation for services provided.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Foundation considers all unrestricted highly liquid investments with an original maturity of three months or less to be cash equivalents. Fair value approximates carrying amounts.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Depreciation

The Foundation follows the practice of capitalizing, at cost, all expenditures for fixed assets in excess of \$5,000. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and Improvements	35 Years
Furniture and Equipment	7 Years
Computers and Accessories	5 Years

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, investments, and notes payable are reported in the statement of financial position at approximate fair values because of the short maturity of those instruments.

NOTE 2 - NET ASSETS WITH DONOR RESTRICTIONS:

The donor restrictions on net assets for the year ended June 30, 2024 consisted of \$8,925 related to Walkathon funding and \$15,000 related to United Way funding for the next year.

NOTE 3 - PROPERTY AND EQUIPMENT:

Property and equipment consisted of the following at June 30, 2024:

	<u>7/01/2023</u>	<u>Additions</u>	<u>Deletions</u>	<u>6/30/2024</u>
Furniture and Equipment	26,940	-	-	26,940
Building	212,444	-	-	212,444
Vehicle	20,907	-	-	20,907
Less Accumulated				
Depreciation	(154,939)	(10,431)	-	(165,370)
Subtotal	105,352	(10,431)	-0-	94,921
Land	1,000	-	-0-	1,000
<u>Total</u>	<u>106,352</u>	<u>(10,431)</u>	<u>-0-</u>	<u>95,921</u>

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 3 - PROPERTY AND EQUIPMENT: (Continued)

Depreciation expense for the year ended June 30, 2024 was \$10,431.

NOTE 4 - COMPENSATED ABSENCES:

Compensated absences are absences for which employees will be paid, such as vacation, sick leave, and sabbatical leave. The Foundation has no policy for compensated absences. Therefore, those costs are not reflected in this report. However, for the purpose of this report the amounts are considered immaterial.

NOTE 5 - DEFERRED REVENUE:

Deferred revenue consists of the following:

United Way Funding	157,560
Walk-a-Thon Funding	3,719
State Genetics Grant	25,595
TAB-N-ACTION	20,617
OPPJ Grant Funding	11,065
JRF Outreach Grant Funding	<u>30,468</u>
<u>Total</u>	<u>249,024</u>

NOTE 6 - FUNCTIONAL ALLOCATION OF EXPENSES:

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefitted.

NOTE 7 - FUND DESCRIPTION:

For internal accounting purposes, the Foundation maintains the following separate funds:

General Fund

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 7 - FUND DESCRIPTION: (Continued)

All assets over which the Board of Directors has discretionary control have been included in the General Fund.

United Way Fund

The United Way Fund is used to account for a grant from United Way of Northeast Louisiana.

Genetic Disease Fund

The Genetic Disease Fund is used to account for a state grant from the Louisiana Department of Health and Hospitals.

Walkathon Fund

The Walkathon Fund is used to account for proceeds from an annual fundraiser.

NOTE 8 - SUBSEQUENT EVENTS:

Events that occur after the balance sheet date but before the financial statements were issued must be evaluated for recognition or disclosure. The effects of subsequent events that provide evidence about conditions that existed after the balance sheet date require disclosure in the accompanying notes. Management evaluated the activity of the Foundation through December 16, 2024, the date the report was available for issue, and concluded that no subsequent events have occurred that would require recognition in the financial statements or disclosures in the notes to the financial statements.

NOTE 9 - LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS:

The following reflects the Foundation's financial assets as of the balance sheet date of June 30, 2024, reduced by amounts not available for general use because of contractual or donor-imposed restrictions within one year of the balance sheet date.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS (CONTINUED)
JUNE 30, 2024

NOTE 9 - LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS: (Continued)

Financial Assets at June 30, 2024	109,355
Less those unavailable for general expenditure within one year, due to:	
Donor Restrictions	<u>23,925</u>
Financial assets availability to meet cash needs for general expenditure, within one year	<u>85,430</u>

In addition to financial assets available to meet general expenditures over the year, the Foundation anticipates covering its general expenditures using the income generated from dues, contributions, and fund-raising events.

NOTE 10 - FUND-RAISING ACTIVITIES:

Details of the special fund-raising events summarized on the statement of activities are as follows:

Banquet Fund-Raising Revenue	5,750
Direct Benefit Costs (Exchange Transaction)	<u>(8,231)</u>
Net (Contribution)	<u>(2,481)</u>
<u>Total Net Fund-Raising Revenue</u>	<u>(2,481)</u>

Other fund-raising costs were not material.

NOTE 11 - CONCENTRATION OF CREDIT RISK:

All cash funds are in institutions insured by an agency of the federal government.

SUPPLEMENTAL INFORMATION

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FINANCIAL POSITION
FOR THE YEAR ENDED JUNE 30, 2024

	Without Donor Restrictions	With Donor Restrictions			
	General Fund	United Way Fund	HSRA Grant Fund	Walkathon Fund	Total All Funds
		<u>Assets</u>			
Current Assets					
Cash and Cash CD	-	10,709	78,536	3,720	92,965
Unconditional					
Promise to Give	-	15,000	1,390	-	16,390
Due from Other Funds	<u>71,320</u>	<u>146,851</u>	<u>9,209</u>	<u>8,924</u>	<u>236,304</u>
<u>Total Current Assets</u>	<u>71,320</u>	<u>172,560</u>	<u>89,135</u>	<u>12,644</u>	<u>345,659</u>
Investments	-	-	-	-	-0-
Physical Properties					
Furniture and	26,940	-	-	-	26,940
Equipment					
Building	212,444	-	-	-	212,444
Vehicle	20,907	-	-	-	20,907
Accumulated					
Depreciation	(165,370)	-	-	-	(165,370)
Land	<u>1,000</u>	-	-	-	<u>1,000</u>
<u>Total Physical</u>					
<u>Properties</u>	<u>95,921</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>95,921</u>
<u>Total Assets</u>	<u>167,241</u>	<u>172,560</u>	<u>89,135</u>	<u>12,644</u>	<u>441,580</u>
<u>Liabilities and Net</u>					
<u>Assets</u>					
Current Liabilities					
Accrued Liabilities	-	-	-	-	-0-
Due to Other Funds	234,914	-	1,390	-	236,304
Deferred Revenue	-	157,560	87,745	3,719	249,024
Line of Credit	-	-	-	-	-0-
<u>Total Current</u>					
<u>Liabilities</u>	<u>234,914</u>	<u>157,560</u>	<u>89,135</u>	<u>3,719</u>	<u>485,328</u>
Long-Term Liabilities	-	-	-	-	-0-
<u>Total Long-Term</u>					
<u>Liabilities</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>
<u>Total Liabilities</u>	<u>234,914</u>	<u>157,560</u>	<u>89,135</u>	<u>3,719</u>	<u>485,328</u>

See Independent Auditors' Report and Accompanying Notes.

SCHEDULE I
(Continued)

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FINANCIAL POSITION (CONTINUED)
FOR THE YEAR ENDED JUNE 30, 2024

	Without Donor <u>Restrictions</u>	<u>With Donor Restrictions</u>			
	General	United	HSRA	Walkathon	Total
	<u>Fund</u>	<u>Fund</u>	<u>Grant</u> <u>Fund</u>	<u>Fund</u>	<u>All Funds</u>
<u>Liabilities and Net Assets</u>					
Net Assets					
Without Donor					
Restrictions	(67,673)	-	-	-	(67,673)
With Donor					
Restrictions	-	15,000	-	8,925	23,925
<u>Total Net Assets</u>	<u>(67,673)</u>	<u>15,000</u>	<u>-0-</u>	<u>8,925</u>	<u>(43,748)</u>
<u>Total Liabilities</u>					
<u>and Net Assets</u>	<u>167,241</u>	<u>172,560</u>	<u>89,135</u>	<u>12,644</u>	<u>441,580</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF ACTIVITIES
FOR THE YEAR ENDED JUNE 30, 2024

	Without Donor Restrictions	With Donor Restrictions			
	General Fund	United Way Fund	HSRA Grant Fund	Walkathon Fund	Total All Funds
<u>Changes in Net Assets Without Donor Restrictions</u>					
Contributions & Grants	56,569	6,332	137,020	3,719	203,640
Other Income	-	-	-	-	-
Investment Income	17	-	-	-	17
Special Events	(2,481)	-	-	-	(2,481)
<u>Total Revenue and Gains Without Donor Restrictions</u>	<u>54,105</u>	<u>6,332</u>	<u>137,020</u>	<u>3,719</u>	<u>201,176</u>
<u>Net Assets Released from Restrictions</u>					
Restrictions Satisfied by Payments	141,852	(6,332)	(137,020)	(3,719)	(5,219)
<u>Total Net Assets Released from Restrictions</u>	<u>141,852</u>	<u>(6,332)</u>	<u>(137,020)</u>	<u>(3,719)</u>	<u>(5,219)</u>
<u>Total Revenue Gains And Other Support Without Donor Restrictions</u>	<u>195,957</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>195,957</u>
<u>Expenses</u>					
Program Expenses	140,389	-	-	-	140,389
General and Administrative Expenses	123,991	-	-	-	123,991
<u>Total Expenses</u>	<u>264,380</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>264,380</u>
<u>Increase (Decrease) in Net Assets Without Donor Restrictions</u>	<u>(68,423)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(68,423)</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF ACTIVITIES (CONTINUED)
FOR THE YEAR ENDED JUNE 30, 2024

	Without Donor Restrictions	With Donor Restrictions			
	General Fund	United Way Fund	HSRA Grant Fund	Walkathon Fund	Total All Funds
<u>Changes in Net Assets With Donor Restrictions</u>					
Contributions	-	-	-	-	-
Grants	-	-	-	-	-
Net Assets Released from Restrictions	-	6,332	137,020	3,719	147,071
Restrictions Satisfied by Payments	-	(4,832)	(137,020)	-	(141,852)
<u>Increase (Decrease) in Net Assets With Donor Restrictions</u>	-0-	1,500	-0-	3,719	5,219
Change in Net Assets	(68,423)	1,500	-	3,719	(63,204)
<u>Net Assets at Beginning of Year</u>	750	13,500	-	5,206	19,456
<u>Net Assets at End of Year</u>	(67,673)	15,000	-0-	8,925	(43,748)

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF CASH FLOWS
FOR THE YEAR ENDED JUNE 30, 2024

	Without Donor <u>Restrictions</u>	<u>With Donor Restrictions</u>			<u>Total All Funds</u>
	<u>General Fund</u>	<u>United Way Fund</u>	<u>HSRA Grant Fund</u>	<u>Walkathon Fund</u>	
<u>Operating Activities</u>					
Change in Net Assets	(68,423)	1,500	-	3,719	(63,204)
Adjustments to Reconcile Change in Net Assets to Net Cash Provided by Operating Activities:					
Provision for Depreciation	10,431	-	-	-	10,431
Decrease (Increase) in Due from Other Funds	64,718	1,569	(19,633)	(3,718)	42,936
Increase (Decrease) in Grants Receivable	-	-	-	-	-
Promise to Give	-	(1,500)	4,616	-	3,116
Accrued Liabilities	-	-	-	-	-
Due to Other Funds	(48,149)	-	5,212	-	(42,936)
Deferred Revenue	-	8,707	87,745	3,719	100,171
Total Adjustments	27,001	8,776	77,940	1	113,718
<u>Net Cash Provided by Operating Activities</u>	(41,422)	10,276	77,940	3,720	50,514

See Independent Auditors' Report and Accompanying Notes.

SCHEDULE III
(Continued)

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF CASH FLOWS (CONTINUED)
FOR THE YEAR ENDED JUNE 30, 2024

	Without Donor Restrictions	With Donor Restrictions			
	General Fund	United Way Fund	HSRA Grant Fund	Walkathon Fund	Total All Funds
<u>Investing Activities</u>					
Purchase of Fixed Assets	-	-	-	-	-0-
Gain on Investment	-	-	-	-	-0-
<u>Net Cash Provided by Investing Activities</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>
<u>Financing Activities</u>					
Payments on Line of Credit	-	-	-	-	-0-
<u>Net Cash Provided by Financing Activities</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>
<u>Net Increase (Decrease) in Cash</u>	(41,422)	10,276	77,940	3,720	50,514
<u>Cash and Cash Equivalents at Beginning of Year</u>	<u>41,422</u>	<u>433</u>	<u>596</u>	<u>-</u>	<u>42,451</u>
<u>Cash and Cash Equivalents at End of Year</u>	<u>-0-</u>	<u>10,709</u>	<u>78,536</u>	<u>3,720</u>	<u>92,965</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES
JUNE 30, 2024

		Net Assets with Donor Restrictions Released From Restriction			
	General	United	HSRA	Walkathon	Total
	Fund	Way	Grant	Fund	All Funds
		Fund	Fund		
<u>Program Expenses</u>					
<u>Personnel Costs</u>					
Salaries and Wages	-	4,463	46,028	-	50,491
Payroll Taxes and Other Fringe Benefits	-	369	3,764	-	4,133
<u>Total Personnel Costs</u>	-	4,832	49,792	-0-	54,624
<u>Other Expenses</u>					
Advertising	6,115	-	-	-	6,115
Automobile Expense	172	-	-	-	172
Bank Charges	-	-	-	-	-
Depreciation Expense	5,633	-	-	-	5,633
Insurance	3,288	-	-	-	3,288
Interest	-	-	-	-	-
Maintenance	1,110	-	-	-	1,110
Office Expense	8,693	-	13,664	-	22,357
Postage and Delivery	158	-	-	-	158
Printing and Publication	1,820	-	-	-	1,820
Program Expenses	1,024	-	-	-	1,024
Repairs and Maintenance	16,124	-	-	-	16,124
Specific Assistance to Individuals	-	-	18,822	-	18,822
Storage	329	-	-	-	329
Telephone	-	-	-	-	-0-
Travel	1,080	-	-	-	1,080
Utilities	7,733	-	-	-	7,733
<u>Total Other Expenses</u>	53,279	-0-	32,486	-0-	85,765
<u>Total Program Expenses</u>	53,279	4,832	82,278	-0-	140,389

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES (CONTINUED)
JUNE 30, 2024

	Net Assets with Donor Restrictions Released From Restriction				
	General	United	HSRA	Walkathon	Total
	Fund	Way	Grant	Fund	All Funds
		Fund	Fund		
<u>General and</u>					
<u>Administrative</u>					
<u>Expenses</u>					
<u>Personnel Costs</u>					
Salaries and Wages	-	-	43,011	-	43,011
Payroll Taxes and Other Fringe Benefits	-	-	3,521	-	3,521
<u>Total Personnel Costs</u>	<u>-0-</u>	<u>-0-</u>	<u>46,532</u>	<u>-0-</u>	<u>46,532</u>
<u>Other Expenses</u>					
Advertising	5,209	-	-	-	5,209
Automobile Expense	147	-	-	-	147
Bank Charges	-	-	-	-	-
Depreciation Expense	4,798	-	-	-	4,798
Interest Expense	-	-	-	-	-
Insurance	2,800	-	-	-	2,800
Maintenance	946	-	-	-	946
Office Expense	10,839	-	8,207	-	19,046
Other Program Expense	873	-	-	-	873
Postage and Delivery	134	-	-	-	134
Printing and Publication	1,551	-	-	-	1,551
Professional Fees	20,432	-	-	-	20,432
Repairs and Maintenance	13,735	-	-	-	13,735
Storage	281	-	-	-	281
Telephone	-	-	-	-	-0-
Travel	920	-	-	-	920
Utilities	6,587	-	-	-	6,587
<u>Total Other Expenses</u>	<u>69,252</u>	<u>-0-</u>	<u>8,207</u>	<u>-0-</u>	<u>77,459</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FUNCTIONAL EXPENSES (CONTINUED)
JUNE 30, 2024

		Net Assets with Donor Restrictions <u>Released From Restriction</u>			
	General <u>Fund</u>	United Way <u>Fund</u>	HSRA Grant <u>Fund</u>	Walkathon <u>Fund</u>	Total <u>All Funds</u>
<u>Total General and Administrative Expenses</u>	<u>69,252</u>	<u>-0-</u>	<u>54,739</u>	<u>-</u>	<u>123,991</u>
<u>Total Functional Expenses</u>	<u>122,531</u>	<u>4,832</u>	<u>137,017</u>	<u>-0-</u>	<u>264,380</u>

See Independent Auditors' Report and Accompanying Notes.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
 SCHEDULE OF COMPENSATION, BENEFITS, AND OTHER PAYMENTS TO
 AGENCY HEAD OR CHIEF EXECUTIVE OFFICER
 FOR THE YEAR ENDED JUNE 30, 2024

AGENCY HEAD NAME/TITLE: DONNA THAXTON, EXECUTIVE DIRECTOR

<u>Purpose</u>	<u>Amount Paid</u>
Salary	44,260
Benefits-insurance	-0-
Benefits-retirement	-0-
Benefits-other (describe)	-0-
Benefits-other (describe)	-0-
Benefits-other (describe)	-0-
Car allowance	-0-
Vehicle provided by government (enter amount reported on W-2)	-0-
Per diem	-0-
Reimbursements	245
Travel	-0-
Registration Fees	-0-
Conference travel	-0-
Housing	-0-
Unvouchered expenses (example: travel advances, etc.)	-0-
Special meals	-0-
Other - Training	-0-

See Independent Auditors' Report and Accompanying Notes.

COMPLIANCE REPORTS

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.

VIOLET M. ROUSSEL, CPA, APC
JAY CUTHBERT, CPA, APAC
DAWN WHITSTINE, CPA, APC



America Counts on CPAs®

Certified Public Accountants
3007 Armand Street
Monroe, Louisiana 71201
Telephone (318) 322-5156
Facsimile (318) 323-6331

- *Accounting & Auditing*
 - HUD Audits
 - Non-Profit Organizations
 - Governmental Organizations
- *Business & Financial Planning*
- *Tax Preparation & Planning*
 - Individual & Partnership
 - Corporate & Fiduciary
- *Bookkeeping & Payroll Services*

PAM BATTAGLIA, CPA
JOHN R. FORSELL, IV, CPA
NICK RICHARDSON, CPA

ROWLAND H. PERRY, CPA-Retired
CHARLES JOHNSON, JR., CPA-Retired

INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors
Northeast Louisiana Sickle Cell Anemia Foundation, Inc.
Monroe, Louisiana

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (a nonprofit organization) which comprise the statement of financial position as of June 30, 2024, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated December 16, 2024.

Report on Internal Control over Financial Reporting

In planning and performing our audit of the financial statements, we considered Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control. Accordingly, we do not express an opinion on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of

the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of non-compliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the organizations internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Johnson Perry Roussel & Cuthbert, LLP

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.
CERTIFIED PUBLIC ACCOUNTANTS
Monroe, Louisiana
December 16, 2024

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF FINDINGS AND QUESTIONED COSTS
FOR THE YEAR ENDED JUNE 30, 2024

Internal Control

There were no findings or questioned costs for the year ended June 30, 2024.

Compliance

There were no findings or questioned costs for the year ended June 30, 2024.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.
SCHEDULE OF PRIOR YEAR FINDINGS
JUNE 30, 2024

Internal Control

There were no findings or questioned costs for the year ended June 30, 2023.

Compliance

There were no findings or questioned costs for the year ended June 30, 2023.